ABSTRACT The use of implantable ventricular assist devices for the treatment of advanced, decompensated heart failure as a bridge to heart transplantation has experienced considerable evolution over the past decade. Improvements in the management and prevention of serious adverse events, and introduction of new continuous-flow rotary pumps that are smaller, more durable, and associated with fewer serious adverse advents has expanded the use of this therapy to a larger population of patients for bridge to transplant indication.
BACKGROUND
Heart transplantation remains the most successful treatment option for patients with advanced heart failure. 1 
As a consequence of limited donor availability, mechanical circulatory support (MCS) in the form of implantable ventricular assist device (VAD) therapy has become an established treatment for patients with advanced heart failure as a bridge to transplantation (BTT)
. [2] [3] [4] The successful clinical use of a ventricular assist device (VAD) as BTT therapy began in the early 1980s. 5 Donald Hill first reported the successful utilization of the pneumatically actuated PierceDonachy paracorporeal device as a BTT. 5 In that same year, Philip Oyer of Stanford University successfully implanted the Novacor left ventricular assist device (LVAD) as a BTT. 6 The Novacor device, developed by Peer Portner, 28 (Fig. 5) . These observations highlight the importance of proper patient selection and Miami, FL, USA) . [31] [32] [33] The DuraHeart LVAD is a CF rotary pump with centrifugal and noncontact-bearing design. 32 The device has a displacement volume of 180 cm 3 
